



New Orleans Office

KEITH M. BENIT, PLC, PARTNER
Admitted in Louisiana and Mississippi

Direct Dial No: (504) 585-7582
Direct Fax No: (504) 544-6040
E-mail: benit@chaffe.com

October 12, 2020

Via US Mail and Email

Stacy Guidry
Section Chief, Medicaid Program Operations and Compliance
State of Louisiana
Louisiana Department of Health
628 N. Fourth St.
P.O. Box 91030
Baton Rouge, LA 70821-9030

Re: **LHCC's Response to LDH Notice of Action - Failure to Incorporate DUR
Retrospective Initiatives as Directed by the Louisiana Department of Health**
Our file no. 54333

Dear Stacy:

We represent Louisiana Healthcare Connections, Inc. ("LHCC") and have been engaged to respond to the September 14, 2020 Notice of Action – Failure to Incorporate DUR Retrospective Initiatives as Directed by the Louisiana Department of Health received by our client. We appreciate you bringing this matter to our attention and want to inform you of the results of our investigation around this issue.

We have been in discussions with our PBM concerning the incorporation of DUR edits relating to the drug Egrifta. Based upon our information and as set forth below, LHCC timely incorporated the edit effective March 1, 2020 and took the necessary steps to remove such edit on August 3, 2020. Below are the screenshots received from our PBM that demonstrates the incorporation and deletion of the edit:

New Orleans: 2300 Energy Centre • 1100 Poydras Street • New Orleans, LA 70163-2300 • Tel: (504) 585-7000 • Fax: (504) 585-7075
Baton Rouge: 103 Two United Plaza • 8550 United Plaza Blvd. • Baton Rouge, LA 70809 • Tel: (225) 922-4300 • Fax: (225) 922-4304
Houston: 801 Travis Street, Suite 1910 • Houston, TX 77002 • Tel: (713) 546-9800 • Fax: (713) 546-9806
Lake Charles: One Lakeshore Drive Suite 1640A • Lake Charles, LA 70629 • Tel: (337) 419-1825 • Fax: (504) 585-7075
www.chaffe.com

3895624-1

Implementation of Egrifta:

2/10/2020	1) Updated the BMG tabs labeled "cDUR DUPHTER" and "cDUR EXCLTHER" with the same named tabs in the attachment BAR case 05074931 submitted, CCD 02/18/2019. Effective 3/1/2020 2) Updated the smartPA attachment in the BMG to include the document : LHCC - 3.1.2020 SmartPAs - Rilutek.Tiglutik.Radicava.Onpatro.Tegsedi.Myobloc.Egrifta.Wakix.Sunosi.Stimulants BAR case 05074987 submitted, CCD 02/19/2019. Effective 3/1/2020	v5.8		Reference column B for BAR case info
-----------	---	------	--	--------------------------------------

Removal of Egrifta:

7/20/2020	1) Updated the smartPA attachment in the BMG to include the document: To Remove the following Smart PA edits with effective date 8/3/2020: o Egrifta	v6.6		BAR case 05469474 submitted on 7/20/20, CCD 7/29/2020 EFFECTIVE 8/03/2020
-----------	---	------	--	---

In addition, attached hereto is our PBM’s step-by-step computer program logic regarding the implementation and subsequent removal of the Egrifta edit. Exhibit A is the logic that was created to include the edit in LHCC’s system. Exhibit B is evidence of the deletion of the edit effective in August 2020.

Finally, our PBM’s records indicate that any Egrifta prescription received for a LHCC member was provided in compliance with LDH requirements.

We understand that our client may have provided LDH certain information indicating that the March 1, 2020 edit was not timely incorporated. We apologize for this error and any inconvenience that it may have caused you or LDH. However, we want to clarify that such edits were timely made and removed and that LHCC takes seriously all of the directives received from LDH.

Again, we appreciate you bringing this matter to our attention and should you have any questions, please do not hesitate to contact me.

Very truly yours,

CHAFFE McCALL, L.L.P.


Keith M. Benit

KMB:mmml
attachment

October 12, 2020

Page 3

cc: (*via email only*)
Michael Boutte
Melanie Doucet
Ruth Johnson
Justin Owens
Kim Sullivan
Christina Wilson
James E. Schlottman
Joe Sullivan
Marshall Ellis

3895624-1

See highlighted changes in yellow
NCPDP Reject Code 39
POS MESSAGE: NCPDP Default

PA Group Description	PA Group ID	Seq. Number	Question	If Yes	If No	Ref. Code	Appendix	Coverage Duration (days)	Approve One Time	Denial Text	Additional Programming Notes
Egrifta	TBD	1	Does the member have a diagnosis of HIV on the incoming claim?	Approve	Deny	Diagnosis	HIV		Y		See Appendix Column H; Diagnosis Code Use SUB DC = S

List Name	GPI Description	List Type	Identifier	Identifier Value
Egrifta	Tesamorelin Acetate For Inj 1 MG (Base Equiv)	Drug	GPI	30150085102120

List Name	Description	List Type	Identifier	Identifier Value
HIV	Human immunodeficiency virus [HIV] disease	Diagnosis	ICD 10	B20

TS #	PA Group Description	Scenario Description	Incoming Claim Properties	Historical Claim Properties	Outcome Pathway	Expected Outcome	Actual Outcome	Comments
1	Egrifta	1) No diagnosis HIV on incoming claim or in history.	Tesamorelin Acetate For Inj 1 MG (NDC 62064001160; GPI 30150085102120) #60/30 days		Step 1 = No	Fail		
2	Egrifta	1) Diagnosis HIV (ICD B20) in member history outside 730 days.	Tesamorelin Acetate For Inj 1 MG (NDC 62064001160; GPI 30150085102120) #60/30 days		Step 1 = No	Fail		
3	Egrifta	1) Diagnosis HIV (ICD B20) in member history within 730 days.	Tesamorelin Acetate For Inj 1 MG (NDC 62064001160; GPI 30150085102120) #60/30 days		Step 1 = Yes	Pass		
4	Egrifta	1) Diagnosis HIV on incoming claim.	ICD B20; Tesamorelin Acetate For Inj 1 MG (NDC 62064001160; GPI 30150085102120) #60/30 days		Step 1 = Yes	Pass		

See highlighted changes in yellow
NCPDP Reject Code 39
POS MESSAGE: NCPDP Default

PA Group- Description	PA Group ID	Seq. Number	Question	If Yes	If No	Ref. Code	Appendix	Coverage- Duration- (days)	Approve- One- Time-	Dental- Text	Additional Programming Notes
Egftta	TBD	1	Does the member have a diagnosis of HIV on the incoming claim?	Approve	Deny	Diagnosis	HIV		X		See Appendix Column H, Diagnosis- Code-Use-SUB DC-S

List Name	GPI Description	List Type	Identifier	Identifier Value
Egftta	Tesamorelin Acetate For Inj 1 MG (Base Equiv)	Drug	GPI	30150085102120

List Name	Description	List Type	Identifier	Identifier Value
HIV	Human immunodeficiency virus (HIV) disease	Diagnosis	ICD 10	B20

TS #	PA Group Description	Scenario Description	Incoming Claim Properties	Historical Claim- Properties	Outcome- Pathway	Expected- Outcome	Actual- Outcome	Comments
1	Egftta	1) No diagnosis HIV on incoming claim- or in history.	Tesamorelin Acetate For Inj 1 MG (NDC 62064001160) GPI 30150085102120) #60/30 days		Step 1 = No	Fail		
2	Egftta	1) Diagnosis HIV (ICD B20) in member- history outside 730 days.	Tesamorelin Acetate For Inj 1 MG (NDC 62064001160) GPI 30150085102120) #60/30 days		Step 1 = No	Fail		
3	Egftta	1) Diagnosis HIV (ICD B20) in member- history within 730 days.	Tesamorelin Acetate For Inj 1 MG (NDC 62064001160) GPI 30150085102120) #60/30 days		Step 1 = Yes	Pass		
4	Egftta	1) Diagnosis HIV on incoming claim.	ICD B20; Tesamorelin Acetate For Inj 1 MG (NDC 62064001160; GPI 30150085102120) #60/30 days		Step 1 = Yes	Pass		